M
itochondria are organelles that generate a rich energy source for cells, which requires their continuous subcellular redistribution via mitochondrial trafficking and mutual repair via mitochondrial fusion (1) . Mitochondrial fusion and subcellular trafficking are mediated in part by mitofusin 1 (MFN1) and MFN2. Genetic mutations in Mfn2 that suppress mitochondrial fusion and motility cause Charcot-Marie-Tooth disease type 2A (CMT2A), the most common inheritable axonal neuropathy (2) . Because no therapeutics exist that directly enhance mitochondrial fusion or trafficking, this disease is unrelenting and irreversible.
Computational modeling based on the closed structure of bacterial dynamin-related protein (BDRP) and the more open structure of optic atrophy-1 suggested that MFN2 can change conformation according to how closely the first and second heptad repeat (HR) domains interact (fig. S1). A closed conformation is fusion incompetent, whereas an open conformation favoring mitochondrial fusion can be induced by a competing peptide analogous to amino acids 367 to 384 within the MFN2 HR1 domain (3) . We identified amino acids controlling these events, first by truncation analysis to define the smallest fusionpromoting minipeptide (residues 374 to 384) ( , which are highly conserved across vertebrate species (figs. S2 and S3), impaired minipeptide-stimulated mitochondrial fusion, as measured by an increase in the mitochondrial length/width ratio (aspect ratio) (Fig. 1C) fig. S1 ), implying a different mechanism for its involvement in mitochondrial fusion.
To address whether Ser 378 might be phosphorylated, we replaced Ser 378 (with Ala, Cys, Asn, or Gly) in the minipeptide and found that phosphorylation and fusion activity were abrogated. Functionality was restored by substituting Asp to mimic phosphorylated Ser or by inserting phospho-Ser itself ( Fig. 1D and fig. S4 with Ala confirmed the HR1-HR2 interaction model (Fig. 1F) .
Nuclear magnetic resonance spectrometry of the minipeptides showed low conformational stability with a propensity to form helical structures. ). Fusion-defective mitochondria in these cells were abnormally short at baseline, but forced expression of wild-type (WT) Ser 378 MFN2 resulted in elongation from restoration of fusion ( Fig. 1H and fig. S10 ). Coexpression of PINK1 with MFN2 or mutational replacement of MFN2 Ser 378 with Asp (which mimics PINK1-mediated Ser 378 phosphorylation) restrained MFN2-stimulated elongation (Fig. 1H  and fig. S10 ). By contrast, MFN2 Ala 378 (which cannot be phosphorylated) promoted mitochondrial fusion resistant to PINK1 suppression ( Fig. 1H and fig. S10 ). The effects of MFN2 Ser 378 mutants were recapitulated in in vitro assays of fusion-mediated mitochondrial content exchange ( fig. S11 ).
We assessed fusogenic activity of commercially available small-molecule candidate pharmacophores (data S2 and supplementary materials and methods), focusing on those having structures that mimicked Ser 378 -phosphorylated (class A) and -unphosphorylated (class B) minipeptide amino acid side chains (fig. S12 and data S3). We reasoned that simultaneous application of class A and B agonists could enhance fig. S12C ). Therefore, we assimilated Cpd A and Cpd B functionality into a single molecule by creating Cpd A-Cpd B chimeras ( Fig. 2A, fig. S14 , and data S4). Chimera B-A/long (B-A/l) potently stimulated mitochondrial fusion in MFN2-deficient cells (Fig. 2B) , competed for minipeptide binding at the MFN2 HR2 interaction site (Fig. 2C) Met 105 (MFN2 T105M) (Fig. 2D) . Fusogenic effects of Cpd A were specific for the Asp 378 mutant of MFN2 that mimicked Ser 378 phosphorylation, whereas Cpd B and chimera B-A/l were nonselective for the phosphomimic Asp 378 and nonphosphorylatable Ala 378 mutants (Fig. 2E) . Because they mimic the WT MFN2 HR1 sequence and interact with HR2, mitofusin agonists evoked fusion to proportionally similar degrees in mitochondria expressing mutants of HR1 that are fusion deficient (Fig. 2F; compare with Fig. 1H  and fig. S6 ). Small-molecule mitofusin agonists required endogenous MFN1 or MFN2 to promote mitochondrial fusion, exhibited no detectable promiscuous activity for structurally related dynamin, and did not compromise cell viability ( fig. S15 ). On the basis of fluorescence resonance energy transfer (FRET) analysis of MFN2 labeled at the N and C termini (supplementary materials and methods), mitofusin agonists promoted an open MFN2 conformation favoring mitochondrial fusion (3), with a rank order paralleling that for HR2 binding and mitochondrial fusion (Fig. 2G; compare with Fig. 2, B and C) , supporting allosteric activation.
In CMT2A, MFN2 mutants produce mitochondrial "fragmentation" (defined as decreased aspect ratio) and loss of normal membrane polarization through dominant inhibition of normal mitofusins. Experiments using MFN1 −/− MFN2 (Fig. 3A) . However, mitofusin agonists corrected the mitochondrial dysmorphology and reversed the mitochondrial hypopolarization induced by these MFN2 mutants when endogenous MFN1 was present (Fig. 3B) . Mitofusin agonists also reversed mitochondrial fragmentation and hypopolarization in cultured mouse neurons expressing (in addition to endogenous mitofusins) CMT2A mutant MFN2 R94Q (Fig. 3 , C and D) or CMT2A mutant MFN2 T105M (Fig. 3E) . Thus, mitofusin agonists do not restore function of CMT2A MFN2 GTPase domain mutants. Rather, by stabilizing the fusionpermissive open conformation of endogenous normal MFN1 or MFN2, mitofusin agonists can overcome dominant suppression of mitochondrial fusion by these disease-causing dysfunctional proteins.
Clinical CMT2A classically affects long nerves innervating the lower and upper limbs (6, 7) . It is unclear how a principal defect in mitochondrial fusion would cause length-dependent neuronal disease. Conversely, disruption of axonal mitochondrial trafficking (8) would be predicted to preferentially affect cells requiring mitochondrial transport over the greatest physical distance, such as the sciatic nerves originating in the spine and terminating in the foot. MFN2 interacts with the Miro/Milton complex to promote mitochondrial motility in neurons (9), so we tested the effects of mitofusin agonism on murine neuronal mitochondrial trafficking. Chimera B-A/l reversed mitochondrial "clumping" (formation of static mitochondrial aggregates) and restored mitochondrial motility in cultured mouse neurons expressing the CMT2A mutant MFN2 T105M (Fig. 4A and  movie S2 ). Mitochondrial hypopolarization and increased autophagy (Fig. 4B and fig. S16 ) and mitochondrial dysmorphology (Fig. 4C and  fig. S16) a small-molecule mitofusin agonist enhanced organelle and cell fitness in CMT2A neurons by promoting mitochondrial fusion and subcellular transport.
We evaluated the concept of activating mitofusins to stimulate in vivo axonal mitochondrial trafficking in sciatic nerves of mice expressing the CMT2A mutant MFN2 T105M. In normal sciatic nerves,~30% of axonal mitochondria exhibited robust bidirectional transport (Fig. 4D and movie S3). Mitochondria of MFN2 T105M sciatic nerves were severely hypomotile ( Fig. 4E and movie S4), but application of chimera B-A/l to MFN2 T105M sciatic nerves restored mitochondrial motility to within normal levels ( Fig.  4F and movie S4) . Mobile mitochondria in WT and B-A/l-treated MFN2 T105M axons were smaller than static mitochondria (Fig. 4G) , supporting in vitro observations discriminating between MFN2-mediated mitochondrial dysmotility and defective fusion in CMT2A (10) .
In this study, we found that PINK1 phosphorylation of MFN2 at Ser 378 can alter the positions of Met 376 and His 380 (in the HR1 domain), which normally interact with HR2 domain amino acids to orchestrate MFN2 toggling between conformations that modulate mitochondrial fusion. These findings establish a mechanistic basis for clinical observations that MFN2 Met 376 mutations to Ile, Thr, and Val can cause CMT2A (7, 11, 12) .
By combining in silico pharmacophore modeling with structural and functional interrogation of MFN2 HR1 domain-derived minipeptides, we developed a novel small-molecule mitofusin agonist that reversed the neuronal mitochondrial dysmorphometry and impaired mobility evoked by two CMT2A Mfn2 mutants. CMT2A is the prototypical clinical disorder of defective mitochondrial fusion, but impaired mitochondrial trafficking may play as great a role as mitochondrial fragmentation in CMT2A axonal degeneration (8) (9) (10) . Individuals with CMT2A express one mutant MFN2 allele in combination with one normal MFN2 allele and harbor two normal MFN1 alleles (13) . It is therefore possible that a therapeutic substrate exists for mitofusin agonists to "supercharge" normal mitofusins and overcome dominant inhibition by MFN2 mutants. Our observation that in vivo mitochondrial dysmotility provoked 
